Trial Profile
A Pilot Study to Evaluate the Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Calcinosis; Systemic scleroderma
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 29 Oct 2021 Results published in the Rheumatology
- 12 Jun 2020 Status changed from active, no longer recruiting to completed.
- 20 Sep 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Jun 2020.